CF3-MQC is an experimental drug developed by Arena Pharmaceuticals, which acts as a reasonably potent and highly selective antagonist for the free fatty acid receptor FFAR3 (GPR41), and is used for research into the function of this receptor.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.